Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing

Clinical Cancer Research

Volumn 17, Issue 18, 2011, Pages 6061-6070

  Herold, Christina I ^a   Chadaram, Vijaya ^b   Peterson, Bercedis L ^b   Marcom, P Kelly ^b   Hopkins, Judith ^c   Kimmick, Gretchen G ^b   Favaro, Justin ^d   Hamilton, Erika ^b   Welch, Renee A ^b   Bacus, Sarah ^e   Blackwell, Kimberly L ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Forsyth Regional Cancer Center   (United States)

^d PRESBYTERIAN HOSPITAL   (United States)

^e IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DASATINIB; FOCAL ADHESION KINASE; PAXILLIN; PROTEIN TYROSINE KINASE; TAXANE DERIVATIVE; TUMOR MARKER;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; ANOREXIA; ARTHRALGIA; BONE PAIN; BREAST BIOPSY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CELLULITIS; CHEMOTHERAPY INDUCED EMESIS; CONFERENCE PAPER; CONSTIPATION; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENZYME INHIBITION; FACE EDEMA; FATIGUE; FEMALE; FLUSHING; HUMAN; HUMAN TISSUE; HYPONATREMIA; INSOMNIA; LIMB PAIN; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RHINITIS; SENSORY NEUROPATHY; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS PP60(C-SRC); PYRIMIDINES; THIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 80052860747     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1071     Document Type: Conference Paper

References (25)

1. Alvarez RH, Kantarjian HM, Cortes JE. The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 2006;107:1918-29. (Pubitemid 44582963)
2. Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 2006;12:1398-401.
3. Roskoski R. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 2005;331:1-14.
4. Brunton VG, Avizienyte E, Fincham VJ, Serrels B, MetcalfIII CA, Sawyer TK, et al. Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior. Cancer Res 2005;65:1335-42. (Pubitemid 40270160)
5. McLean GW, Fincham VJ, Frame MC. v-Src induces tyrosine phosphorylation of focal adhesion kinase independently of tyrosine 397 and formation of a complex with Src. J Biol Chem 2000;275:23333-9. (Pubitemid 30646235)
6. Rodina A, Schramm K, Musatkina E, Kreuserb E, Tavitianc A, Tatosyana A. Phosphorylation of p125FAK and pax focal adhesion proteins in src-transformed cells with different metastatic capacity. FEBS Lett 1999;455:145-8. (Pubitemid 29322798)
7. Jones RJ, Young O, Renshaw L, Jacobs V, Fennell M, Marshall A, et al. Src inhibitors in early breast caner: a methodology, feasibility and variability study. Breast Cancer Res Treat 2009;114:211-21.
8. Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, et al. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res 2010;16:4876-83.
9. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76. (Pubitemid 32452017)
10. Miyazaki T, Sanjay A, Neff L, Tanaka S, Horne WC, Baron R. Src kinase activity is essential for osteoclast function. J Biol Chem 2004;279:17660-6. (Pubitemid 38560531)
11. Myoui A, Nishimura R, Williams PJ, Hiraga T, Tamura D, Michigami T, et al. C-Src tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastases. Cancer Res 2003;63:5028-33. (Pubitemid 37022641)
12. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1- yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61. (Pubitemid 40053752)
13. Lee FY, Lombardo L, Camuso A, Castaneda S, Fager K, Flefleh C, et al. BMS- 354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broadspectrum antitumor activities in vitro and in vivo [abstract 675]. Proc Am Assoc Cancer Res 2005;46:159.
14. Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, et al. Phase I dose escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 2009;15:6232-40.
15. Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 2010;116:1582-91.
16. Introduction to antibodies, 2nd ed. Temecula (CA): Chemicon international-A Division of Serologicals Corp.; 2005.
17. Positive Pixel Count Algorithm User's Guide. Vista (CA): Aperio Technologies, Inc.; 2009.
18. Jung S, Lee T, Kim KM, George SL. Admissible two-stage designs for phase II cancer clinical trials. Stat in Med 2004;23:561-9. (Pubitemid 38208184)
19. Finn R, Bengala C, Ibrahim N, Strauss LC, Fairchild J, Sy O, et al. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059 [abstract]. Cancer Res 2009;69(2 Suppl):3118.
20. Mayer E, Baurain J, Sparano J, Strauss L,CamponeM, Fumoleau P, et al. Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: phase II study CA180088 [abstract 1011]. J Clin Oncol 2009;27 (15S, Part I):43s.
21. Moreno-Aspitia A, Morton RF, Hillman DW, Lingle WL, Rowland Jr KM, Wiesenfeld M, et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 2009;27:11-5.
22. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, et al. Phase 2 study of dasatinib in patients with metastatic castrationresistant prostate cancer. Clin Cancer Res 2009;15:7421-8.
23. NCT00566618. Dasatinib in combination with zolendronic acid for the treatment of breast cancer with bone metastasis [cited 2011 Aug 15]. Available from: http://www.clinicaltrials.gov.
24. Bergh J. Quo vadis with targeted drugs in the 21st century? J Clin Oncol 2009;27:2-5.
25. Pintilie M, Iakovlev V, Fyles A, Hedley D, Milosevic M, Hill RP. Heterogeneity and power in clinical biomarker studies. J Clin Oncol 2009;27:1517-21.